222 related articles for article (PubMed ID: 31571292)
1. The role of polo-like kinase 3 in the response of BRAF-mutant cells to targeted anticancer therapies.
Babagana M; Kichina JV; Slabodkin H; Johnson S; Maslov A; Brown L; Attwood K; Nikiforov MA; Kandel ES
Mol Carcinog; 2020 Jan; 59(1):5-14. PubMed ID: 31571292
[TBL] [Abstract][Full Text] [Related]
2. Immunomodulatory effects of BRAF and MEK inhibitors: Implications for Melanoma therapy.
Kuske M; Westphal D; Wehner R; Schmitz M; Beissert S; Praetorius C; Meier F
Pharmacol Res; 2018 Oct; 136():151-159. PubMed ID: 30145328
[TBL] [Abstract][Full Text] [Related]
3. Indoleamine 2,3-dioxygenase in melanoma progression and BRAF inhibitor resistance.
Sandri S; Watanabe LRM; Oliveira EA; Faião-Flores F; Migliorini S; Tiago M; Felipe-Silva A; Vazquez VL; da Costa Souza P; Consolaro MEL; Campa A; Maria-Engler SS
Pharmacol Res; 2020 Sep; 159():104998. PubMed ID: 32535222
[TBL] [Abstract][Full Text] [Related]
4. Dual MAPK Inhibition Is an Effective Therapeutic Strategy for a Subset of Class II BRAF Mutant Melanomas.
Dankner M; Lajoie M; Moldoveanu D; Nguyen TT; Savage P; Rajkumar S; Huang X; Lvova M; Protopopov A; Vuzman D; Hogg D; Park M; Guiot MC; Petrecca K; Mihalcioiu C; Watson IR; Siegel PM; Rose AAN
Clin Cancer Res; 2018 Dec; 24(24):6483-6494. PubMed ID: 29903896
[TBL] [Abstract][Full Text] [Related]
5. Vemurafenib Drives Epithelial-to-Mesenchymal Transition Gene Expression in BRAF Inhibitor‒Resistant BRAF
Jandova J; Wondrak GT
J Invest Dermatol; 2022 May; 142(5):1456-1465.e1. PubMed ID: 34687745
[TBL] [Abstract][Full Text] [Related]
6. Sestrin2 contributes to BRAF inhibitor resistance via reducing redox vulnerability of melanoma cells.
Guo S; Yue Q; Wang S; Wang H; Ye Z; Zhang W; Shi Q; Gao T; Li C; Zhu G
J Dermatol Sci; 2023 Feb; 109(2):52-60. PubMed ID: 36858850
[TBL] [Abstract][Full Text] [Related]
7. Resistance to BRAF Inhibitors: EZH2 and Its Downstream Targets as Potential Therapeutic Options in Melanoma.
Uebel A; Kewitz-Hempel S; Willscher E; Gebhardt K; Sunderkötter C; Gerloff D
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768289
[TBL] [Abstract][Full Text] [Related]
8. Targeting Extracellular Matrix Remodeling Restores BRAF Inhibitor Sensitivity in BRAFi-resistant Melanoma.
Marusak C; Thakur V; Li Y; Freitas JT; Zmina PM; Thakur VS; Chang M; Gao M; Tan J; Xiao M; Lu Y; Mills GB; Flaherty K; Frederick DT; Miao B; Sullivan RJ; Moll T; Boland GM; Herlyn M; Zhang G; Bedogni B
Clin Cancer Res; 2020 Nov; 26(22):6039-6050. PubMed ID: 32820016
[TBL] [Abstract][Full Text] [Related]
9. M-CSF as a therapeutic target in BRAF
Barceló C; Sisó P; de la Rosa I; Megino-Luque C; Navaridas R; Maiques O; Urdanibia I; Eritja N; Soria X; Potrony M; Calbet-Llopart N; Puig S; Matías-Guiu X; Martí RM; Macià A
Br J Cancer; 2022 Oct; 127(6):1142-1152. PubMed ID: 35725813
[TBL] [Abstract][Full Text] [Related]
10. BRAFi induced demethylation of miR-152-5p regulates phenotype switching by targeting TXNIP in cutaneous melanoma.
Li K; Tang M; Tong S; Wang C; Sun Q; Lv M; Sun X; Wang T; Jin S
Apoptosis; 2020 Apr; 25(3-4):179-191. PubMed ID: 32056038
[TBL] [Abstract][Full Text] [Related]
11. A Review of the Molecular Pathways Involved in Resistance to BRAF Inhibitors in Patients with Advanced-Stage Melanoma.
Tian Y; Guo W
Med Sci Monit; 2020 Apr; 26():e920957. PubMed ID: 32273491
[TBL] [Abstract][Full Text] [Related]
12. Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib.
Acquaviva J; Smith DL; Jimenez JP; Zhang C; Sequeira M; He S; Sang J; Bates RC; Proia DA
Mol Cancer Ther; 2014 Feb; 13(2):353-63. PubMed ID: 24398428
[TBL] [Abstract][Full Text] [Related]
13. BRAF Inhibitors in Melanoma Management: When Friends Become Foes.
Chhabra G; Ahmad N
J Invest Dermatol; 2022 May; 142(5):1256-1259. PubMed ID: 34872726
[TBL] [Abstract][Full Text] [Related]
14. WNT5A enhances resistance of melanoma cells to targeted BRAF inhibitors.
Anastas JN; Kulikauskas RM; Tamir T; Rizos H; Long GV; von Euw EM; Yang PT; Chen HW; Haydu L; Toroni RA; Lucero OM; Chien AJ; Moon RT
J Clin Invest; 2014 Jul; 124(7):2877-90. PubMed ID: 24865425
[TBL] [Abstract][Full Text] [Related]
15. ER Translocation of the MAPK Pathway Drives Therapy Resistance in BRAF-Mutant Melanoma.
Ojha R; Leli NM; Onorati A; Piao S; Verginadis II; Tameire F; Rebecca VW; Chude CI; Murugan S; Fennelly C; Noguera-Ortega E; Chu CT; Liu S; Xu X; Krepler C; Xiao M; Xu W; Wei Z; Frederick DT; Boland G; Mitchell TC; Karakousis GC; Schuchter LM; Flaherty KT; Zhang G; Herlyn M; Koumenis C; Amaravadi RK
Cancer Discov; 2019 Mar; 9(3):396-415. PubMed ID: 30563872
[TBL] [Abstract][Full Text] [Related]
16. Inhibiting BRAF Oncogene-Mediated Radioresistance Effectively Radiosensitizes BRAF
Robb R; Yang L; Shen C; Wolfe AR; Webb A; Zhang X; Vedaie M; Saji M; Jhiang S; Ringel MD; Williams TM
Clin Cancer Res; 2019 Aug; 25(15):4749-4760. PubMed ID: 31097454
[TBL] [Abstract][Full Text] [Related]
17. Ibrutinib Blocks YAP1 Activation and Reverses BRAF Inhibitor Resistance in Melanoma Cells.
Misek SA; Newbury PA; Chekalin E; Paithankar S; Doseff AI; Chen B; Gallo KA; Neubig RR
Mol Pharmacol; 2022 Jan; 101(1):1-12. PubMed ID: 34732527
[TBL] [Abstract][Full Text] [Related]
18. Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor-Refractory Metastatic Melanoma: A Phase 2 Clinical Trial.
Chen G; McQuade JL; Panka DJ; Hudgens CW; Amin-Mansour A; Mu XJ; Bahl S; Jané-Valbuena J; Wani KM; Reuben A; Creasy CA; Jiang H; Cooper ZA; Roszik J; Bassett RL; Joon AY; Simpson LM; Mouton RD; Glitza IC; Patel SP; Hwu WJ; Amaria RN; Diab A; Hwu P; Lazar AJ; Wargo JA; Garraway LA; Tetzlaff MT; Sullivan RJ; Kim KB; Davies MA
JAMA Oncol; 2016 Aug; 2(8):1056-64. PubMed ID: 27124486
[TBL] [Abstract][Full Text] [Related]
19. Sustained SREBP-1-dependent lipogenesis as a key mediator of resistance to BRAF-targeted therapy.
Talebi A; Dehairs J; Rambow F; Rogiers A; Nittner D; Derua R; Vanderhoydonc F; Duarte JAG; Bosisio F; Van den Eynde K; Nys K; Pérez MV; Agostinis P; Waelkens E; Van den Oord J; Fendt SM; Marine JC; Swinnen JV
Nat Commun; 2018 Jun; 9(1):2500. PubMed ID: 29950559
[TBL] [Abstract][Full Text] [Related]
20. Mitochondrial complex I inhibitor deguelin induces metabolic reprogramming and sensitizes vemurafenib-resistant BRAF
Carpenter EL; Chagani S; Nelson D; Cassidy PB; Laws M; Ganguli-Indra G; Indra AK
Mol Carcinog; 2019 Sep; 58(9):1680-1690. PubMed ID: 31211467
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
